Inflammation Could Prove Meaningful Target in Myasthenia Gravis
New therapeutic strategies to treat myasthenia gravis (MG) ought to exploit the apparent association between the disease and inflammation, according to a new review published in Frontiers in Immunology.
This analysis argues that a better understanding of the role of inflammation could lead to the development of better therapies or of combination therapies that target both the autoantibody and inflammatory components of MG.
MG is a chronic autoimmune disease in which autoantibodies bind to acetylcholine receptors (AChRs), thereby reducing their functionality and leading to symptoms like muscle weakness and fatigue. However, the study author noted that inflammation is also a common feature of the disease. [read more]
